Repurposing of cyclophilin A inhibitors as broad-spectrum antiviral agents

Cyclophilin A: a key player for etiological agent infection

(2021) Yating Liao et al.   APPLIED MICROBIOLOGY AND BIOTECHNOLOGY

Cytoplasmic CPSF6 Regulates HIV-1 Capsid Trafficking and Infection in a Cyclophilin A-Dependent Manner

(2021) Zhou Zhong et al.   mBio

Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2

(2021) Mark Dittmar et al.   Cell Reports

Current and Future Antiviral Strategies to Tackle Gastrointestinal Viral Infections

(2021) Nanci Santos-Ferreira et al.   Microorganisms

Molecular design, synthesis, and biological evaluation of bisamide derivatives as cyclophilin A inhibitors for HCV treatment

(2020) Jinhe Han et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Inhibition of SARS-CoV-2 infection by the cyclophilin inhibitor Alisporivir (Debio 025)

(2020) Laurent Softic et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cyclophilin A inhibitor Debio-025 targets Crk, reduces metastasis, and induces tumor immunogenicity in breast cancer

(2020) Viralkumar Davra et al.   MOLECULAR CANCER RESEARCH

Cyclophilin A Prevents HIV-1 Restriction in Lymphocytes by Blocking Human TRIM5α Binding to the Viral Core

(2020) Anastasia Selyutina et al.   Cell Reports

Cyclophilin Inhibitors Restrict Middle East Respiratory Syndrome Coronavirus Via Interferon λ In Vitro And In Mice

(2020) Lucie Sauerhering et al.   EUROPEAN RESPIRATORY JOURNAL

ISGylation of hepatitis C virus NS5A protein promotes viral RNA replication via the recruitment of cyclophilin A

(2020) Takayuki Abe et al.   JOURNAL OF VIROLOGY

Intrinsic curvature of the HIV-1 CA hexamer underlies capsid topology and interaction with cyclophilin A

(2020) Tao Ni et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Hepatitis C virus exploits cyclophilin A to evade PKR

(2020) Che C Colpitts et al.   eLife

SAR study of bisamides as cyclophilin a inhibitors for the development of host-targeting therapy for hepatitis C virus infection

(2020) Xiaoli Li et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B

(2020) Maria Pfefferkorn et al.   JOURNAL OF HEPATOLOGY

Nuclear Import of the HIV-1 Core Precedes Reverse Transcription and Uncoating

(2020) Anastasia Selyutina et al.   Cell Reports

Expression of CD147 and Cyclophilin A in Kidneys of Patients with COVID-19

(2020) Hua Su et al.   Clinical Journal of the American Society of Nephrology

Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets

(2020) Robert M. Cox et al.   Nature Microbiology

The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice

(2019) Philippe Gallay et al.   PLoS One

Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia

(2019) Mart Toots et al.   Science Translational Medicine

Cyclophilin A protects HIV-1 from restriction by human TRIM5α

(2019) Kyusik Kim et al.   Nature Microbiology

Overcoming the legal and regulatory barriers to drug repurposing

(2018) Alasdair Breckenridge et al.   NATURE REVIEWS DRUG DISCOVERY

Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle

(2018) Richard L. Mackman et al.   JOURNAL OF MEDICINAL CHEMISTRY

Nuclear pore heterogeneity influences HIV-1 infection and the antiviral activity of MX2

(2018) Melissa Kane et al.   eLife

CypA Regulates AIP4-Mediated M1 Ubiquitination of Influenza A Virus

(2018) Madina Mahesutihan et al.   VIROLOGICA SINICA

Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity

(2017) Satomi Shimura et al.   JOURNAL OF HEPATOLOGY

Discovery of Potent Cyclophilin Inhibitors Based on the Structural Simplification of Sanglifehrin A

(2017) Victoria A. Steadman et al.   JOURNAL OF MEDICINAL CHEMISTRY

Cyclophilin A-regulated ubiquitination is critical for RIG-I-mediated antiviral immune responses

(2017) Wei Liu et al.   eLife

Mycophenolic acid potently inhibits rotavirus infection with a high barrier to resistance development

(2016) Yuebang Yin et al.   ANTIVIRAL RESEARCH

Design and synthesis of peptide-based macrocyclic cyclophilin inhibitors

(2016) Brett A. Granger et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Small ruminant lentiviral Vif proteins commonly utilize cyclophilin A, an evolutionarily and structurally conserved protein, to degrade ovine and caprine APOBEC3 proteins

(2016) Rokusuke Yoshikawa et al.   MICROBIOLOGY AND IMMUNOLOGY

Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities

(2016) Abdelhakim Ahmed-Belkacem et al.   Nature Communications

Cyclophilin A protects mice against infection by influenza A virus

(2016) Jing Li et al.   Scientific Reports

Nuclear Envelope Protein SUN2 Promotes Cyclophilin-A-Dependent Steps of HIV Replication

(2016) Xavier Lahaye et al.   Cell Reports

The Hepatitis C Virus-Induced Membranous Web and Associated Nuclear Transport Machinery Limit Access of Pattern Recognition Receptors to Viral Replication Sites

(2016) Christopher J. Neufeldt et al.   PLoS Pathogens

Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175

(2016) Philippe A. Gallay et al.   PLoS One

Cyclophilin and NS5A Inhibitors, but Not Other Anti-Hepatitis C Virus (HCV) Agents, Preclude HCV-Mediated Formation of Double-Membrane-Vesicle Viral Factories

(2015) Udayan Chatterji et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Bioengineering and Semisynthesis of an Optimized Cyclophilin Inhibitor for Treatment of Chronic Viral Infection

(2015) Magnus Joakim Hansson et al.   CHEMISTRY & BIOLOGY

Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections

(2015) Suhui Yang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Novel Small Molecule Anti-HCV Agents via the CypA Inhibitory Mechanism Using O-Acylation-Directed Lead Optimization

(2015) Wenzhong Yan et al.   MOLECULES

Genetic deficiency and polymorphisms of cyclophilin A reveal its essential role for Human Coronavirus 229E replication

(2015) Albrecht von Brunn et al.   Current Opinion in Virology

The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action

(2015) Philippe A. Gallay et al.   PLoS One

Macrophage Infection via Selective Capture of HIV-1-Infected CD4+ T Cells

(2014) Amy E. Baxter et al.   Cell Host & Microbe

Hepatitis C Virus RNA Replication and Assembly: Living on the Fat of the Land

(2014) David Paul et al.   Cell Host & Microbe

NIM811, a cyclophilin inhibitor without immunosuppressive activity, is beneficial in collagen VI congenital muscular dystrophy models

(2014) A. Zulian et al.   HUMAN MOLECULAR GENETICS

The Nuclear Export Protein of H5N1 Influenza A Viruses Recruits Matrix 1 (M1) Protein to the Viral Ribonucleoprotein to Mediate Nuclear Export

(2014) Linda Brunotte et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Innate and adaptive immune responses in HCV infections

(2014) Markus H. Heim et al.   JOURNAL OF HEPATOLOGY

Potent Nonimmunosuppressive Cyclophilin Inhibitors With Improved Pharmaceutical Properties and Decreased Transporter Inhibition

(2014) Jiping Fu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Cyclophilin A catalyzes proline isomerization by an electrostatic handle mechanism

(2014) C. Camilloni et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir

(2014) Javier Carbajo-Lozoya et al.   VIRUS RESEARCH

Correction: Essential Role of Cyclophilin A for Hepatitis C Virus Replication and Virus Production and Possible Link to Polyprotein Cleavage Kinetics

(2014) Artur Kaul et al.   PLoS Pathogens

Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP)

(2013) Koichi Watashi et al.   HEPATOLOGY

1213 CYCLOPHILIN INHIBITOR EDP-546 IS A POTENTIAL CORNERSTONE DRUG FOR USE IN COMBINATION WITH NS5A AND PROTEASE INHIBITORS DUE TO ITS HIGH BARRIER TO HCV RESISTANCE

(2013) C.M. Owens et al.   JOURNAL OF HEPATOLOGY

Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor

(2013) Shirin Nkongolo et al.   JOURNAL OF HEPATOLOGY

Anti-inflammatory Effects of Extracellular Cyclosporins Are Exclusively Mediated by CD147

(2013) Miroslav Malesevic et al.   JOURNAL OF MEDICINAL CHEMISTRY

Tyrosine 132 Phosphorylation of Influenza A Virus M1 Protein Is Crucial for Virus Replication by Controlling the Nuclear Import of M1

(2013) S. Wang et al.   JOURNAL OF VIROLOGY

Technologies for the Synthesis of mRNA-Encoding Libraries and Discovery of Bioactive Natural Product-Inspired Non-Traditional Macrocyclic Peptides

(2013) Kenichiro Ito et al.   MOLECULES

Completion of the entire hepatitis C virus life cycle in genetically humanized mice

(2013) Marcus Dorner et al.   NATURE

Proteomic methods reveal cyclophilin a function as a host restriction factor against rotavirus infection

(2013) Haiyang He et al.   PROTEOMICS

Interaction of immunosuppressive drugs with human organic anion transporter (OAT) 1 and OAT3, and multidrug resistance-associated protein (MRP) 2 and MRP4

(2013) Azza A.K. El-Sheikh et al.   Translational Research

The Cyclophilin Inhibitor SCY-635 Disrupts Hepatitis C Virus NS5A-Cyclophilin A Complexes

(2012) Sam Hopkins et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cyclophilin A inhibits rotavirus replication by facilitating host IFN-I production

(2012) Haiyang He et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Update on alisporivir in treatment of viral hepatitis C

(2012) Robert Flisiak et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Discovery of novel low-molecular-weight HIV-1 inhibitors interacting with cyclophilin A using in silico screening and biological evaluations

(2012) Yu-Shi Tian et al.   JOURNAL OF MOLECULAR MODELING

A Nuclear Export Signal in the Matrix Protein of Influenza A Virus Is Required for Efficient Virus Replication

(2012) S. Cao et al.   JOURNAL OF VIROLOGY

Apolipoprotein E controls cerebrovascular integrity via cyclophilin A

(2012) Robert D. Bell et al.   NATURE

Three-Dimensional Architecture and Biogenesis of Membrane Structures Associated with Hepatitis C Virus Replication

(2012) Inés Romero-Brey et al.   PLoS Pathogens

Bile salt export pump inhibitors are associated with bile acid-dependent drug-induced toxicity in sandwich-cultured hepatocytes

(2011) Eiichiro Ogimura et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Design and Synthesis of Conformationally Constrained Cyclophilin Inhibitors Showing a Cyclosporin-A Phenotype in C. elegans

(2011) Colin J. Dunsmore  et al.   CHEMBIOCHEM

The pathogenesis of influenza virus infections: the contributions of virus and host factors

(2011) Satoshi Fukuyama et al.   CURRENT OPINION IN IMMUNOLOGY

Discovery of a potent peptidic cyclophilin A inhibitor Trp-Gly-Pro

(2011) Xiaodong Pang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Computational Insight into Small Molecule Inhibition of Cyclophilins

(2011) Somisetti V. Sambasivarao et al.   Journal of Chemical Information and Modeling

Virulence determinants of pandemic influenza viruses

(2011) Donna M. Tscherne et al.   JOURNAL OF CLINICAL INVESTIGATION

The SARS-Coronavirus-Host Interactome: Identification of Cyclophilins as Target for Pan-Coronavirus Inhibitors

(2011) Susanne Pfefferle et al.   PLoS Pathogens

Mechanism of Resistance of Hepatitis C Virus Replicons to Structurally Distinct Cyclophilin Inhibitors

(2010) X. Puyang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Synthesis and biological evaluation of [d-lysine]8cyclosporin A analogs as potential anti-HCV agents

(2010) Andrew Scribner et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Cyclosporine A, but Not Tacrolimus, Shows Relevant Inhibition of Organic Anion-Transporting Protein 1B1-Mediated Transport of Atorvastatin

(2010) R. Amundsen et al.   DRUG METABOLISM AND DISPOSITION

676 IN VITRO MODELS FOR ASSESSING THE RELATIVE RISK OF HYPERBILIRUBINEMIA ASSOCIATED WITH CYCLOPHILIN INHIBITOR THERAPY

(2010) S. Wring et al.   JOURNAL OF HEPATOLOGY

HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A–cyclophilin A interaction to cyclophilin inhibitors

(2010) Udayan Chatterji et al.   JOURNAL OF HEPATOLOGY

DEB025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A

(2010) Lotte Coelmont et al.   PLoS One

Structural and Biochemical Characterization of the Human Cyclophilin Family of Peptidyl-Prolyl Isomerases

(2010) Tara L. Davis et al.   PLOS BIOLOGY

SCY-635, a Novel Nonimmunosuppressive Analog of Cyclosporine That Exhibits Potent Inhibition of Hepatitis C Virus RNA Replication In Vitro

(2009) S. Hopkins et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

EMMPRIN and its ligand cyclophilin A regulate MT1-MMP, MMP-9 and M-CSF during foam cell formation

(2009) Peter Seizer et al.   ATHEROSCLEROSIS

Isoform-Specific Inhibition of Cyclophilins

(2009) Sebastian Daum et al.   BIOCHEMISTRY

Discovery of dual inhibitors targeting both HIV-1 capsid and human cyclophilin A to inhibit the assembly and uncoating of the viral capsid

(2009) Jiebo Li et al.   BIOORGANIC & MEDICINAL CHEMISTRY

The cyclophilin inhibitor Debio 025 normalizes mitochondrial function, muscle apoptosis and ultrastructural defects inCol6a1−/−myopathic mice

(2009) T Tiepolo et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cyclophilin A interacts with influenza A virus M1 protein and impairs the early stage of the viral replication

(2009) Xiaoling Liu et al.   CELLULAR MICROBIOLOGY

Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A

(2009) Sandra Ciesek et al.   HEPATOLOGY

The Isomerase Active Site of Cyclophilin A Is Critical for Hepatitis C Virus Replication

(2009) Udayan Chatterji et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Discovering Potent Small Molecule Inhibitors of Cyclophilin A Using de Novo Drug Design Approach

(2009) Shuaishuai Ni et al.   JOURNAL OF MEDICINAL CHEMISTRY

Crystal structure of cyclophilin A complexed with a binding site peptide from the HIV-1 capsid protein

(2009) Felix F. Vajdos et al.   PROTEIN SCIENCE

Modulation of HIV-1 infectivity and cyclophilin A-dependence by Gag sequence and target cell type

(2009) Saori Matsuoka et al.   Retrovirology

The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus

(2008) Robert Flisiak et al.   HEPATOLOGY

Cyclophilin A Is an Essential Cofactor for Hepatitis C Virus Infection and the Principal Mediator of Cyclosporine Resistance In Vitro

(2008) F. Yang et al.   JOURNAL OF VIROLOGY

Cellular Proteins in Influenza Virus Particles

(2008) Megan L. Shaw et al.   PLoS Pathogens